Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hematological Malignancies: early-phase trial registry
5 of 17 indexed Hematological Malignancies trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,004 of 28,707 conditions by registered trial count.
17 US clinical trials · 5 currently recruiting · #1,004 of 28,707 conditions by registered trial count
Hematological Malignancies: 17 US clinical trials tracked, 5 recruiting.
Hematological Malignancies is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is Janssen Research & Development, running 4 of these trials.
Enrollment posture brief
Registry condition hematological-malignancies
OPEN 5 | RECR 29% | LATE 1 | EARLY 13 | RANK #1004 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Addiction (29% recruiting · 17 trials)
Hematological Malignancies lists 5 open slots (29% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hematological Malignancies on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hematological Malignancies is recruiting below its size-band peers.
5 of 17 indexed trials (29.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Hematological Malignancies research.
Janssen Research & Development accounts for 4 of 17 trials (23.5%). 12 distinct sponsors appear on at least one study for this condition label.
-
Typical Hematological Malignancies enrolment sits around 106 participants.
Median target enrolment is 106 among the 17 trials that report a genuine target (sentinel values excluded). 8 of those (47.1%) plan for fewer than 100 participants.
-
Hematological Malignancies research is mostly interventional.
15 interventional and 2 observational studies make up this index (88.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
17 total, page 1 of 1
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Dana-Farber Cancer Institute
NCT02269592
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development
NCT04634552
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Daiichi Sankyo
NCT07220616
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
University of Nebraska
NCT06799195
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
Smart Immune SAS
NCT04959903
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development
NCT03145181
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development
NCT03399799
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development
NCT04557098
Study of AZD9829 in CD123+ Hematological Malignancies
AstraZeneca
NCT06179511
Durvalumab and Tremelimumab for Pediatric Malignancies
AstraZeneca
NCT03837899
Feasibility of the Use of Weighted Blankets to Improve Sleep Among Patients With Hematological Malignancies
M.D. Anderson Cancer Center
NCT06584955
A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)
Merck Sharp & Dohme
NCT05005442
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Mundipharma Research Limited
NCT02576496
The Good Patient Study
St. Jude Children's Research Hospital
NCT02199548
Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM
Gamida Cell
NCT01816230
Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Gamida Cell
NCT04260698
Compassionate Use Study of Tenalisib (RP6530)
Rhizen Pharmaceuticals
NCT03711604
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 4 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Hematological Malignancies records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hematological Malignancies trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hematological Malignancies page
17 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Hematological Malignancies trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Janssen Research & Development sponsors the most Hematological Malignancies trials on record, review their full trial history before evaluating a specific study. See Janssen Research & Development's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hematological Malignancies condition card totals 17 registered trials; most-linked intervention Talquetamab; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.